110
Participants
Start Date
April 12, 2021
Primary Completion Date
March 31, 2025
Study Completion Date
May 31, 2025
Indomethacin 25 MG/50 MG
Indomethacin is a nonsteroidal anti-inflammatory drug commonly used to reduce fever, pain, stiffness, and swelling from inflammation. It prevents the production of prostaglandins, endogenous signaling molecules known to cause symptoms from inflammation. Indomethacin is used to test COX as a potential mechanism explaining sex differences in CBF control. Indomethacin usage is IND exempt.
Placebo - Lactose
Participants will be screened for lactose intolerance. Total dosing will be calculated to match the mg needed for the indomethacin study visit. Placebo usage is IND exempt.
Ganirelix Acetate
"Gonadotropin-Releasing Hormone (GnRH) antagonist ganirelix acetate as a model to isolate estrogen and testosterone effects on the cerebrovascular system. Participants receive daily injections of ganirelix for 12-14 days for Aim 3 studies only. This will be overseen by clinical endocrinologists.~Both males and females receive this treatment in Aim 3."
Testosterone Transdermal Product
In Aim 3, males receive this for 7-9 days of the ganirelix treatment.
Estradiol Topical
In Aim 3, females receive this for 7-9 days of the ganirelix treatment.
Antacid
Participants will be given a dose of over-the-counter antacid to combat the gastrointestinal distress expected from Indomethacin. Participants will be given a dose of over-the-counter antacid during the placebo visit to mimic the indomethacin study visit. Antacid is IND exempt.
University of Wisconsin, Madison, Madison
National Heart, Lung, and Blood Institute (NHLBI)
NIH
University of Wisconsin, Madison
OTHER